Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Amyotrophic Lateral Sclerosis (ALS) · Parkinson Disease (PD) · Alzheimer Disease (AD) · Multiple Sclerosis (MS)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UCSF, San Francisco, California, United States
Stanford University, Stanford, California, United States
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Contact: Study coordinator (Colette McHugh-Strong, JD) · McHugh-Strong.Colette@mayo.edu · 904-953-4965
Study leads
Farshad Moradi, MD
Principal Investigator
Stanford University